On August 18, Eli Lilly rose 3.1% in regular trading, trading at $1,220.49/share, with turnover of $9.18 billion. The stock benefited from a broad rally in obesity drug concept stocks against the overall healthcare sector weakness, combined with multiple pipeline collaboration announcements.

On the news front, Eli Lilly entered a global collaboration and license agreement with OmniAb for a new ion channel drug discovery program, with OmniAb eligible to receive up to $370 million in milestone payments plus tiered royalties on global net sales. Separately, Eli Lilly completed a $10 million upfront payment to AlzeCure Pharma under their Alzheimer's disease Alzstatin collaboration. Meanwhile, the company recently initiated a Phase III clinical trial of Brenipatide, its second GLP-1/GIP dual-agonist, for adult depression in China.

The broader GLP-1 sector rallied against the market trend, with the NYSE Healthcare Index down 0.2% while Eli Lilly outperformed as a sector leader. Analyst consensus maintains an overweight rating with a mean price target of $1,345.58.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)